Fennec Pharmaceuticals (TSE:FRX) Insider Sells C$265,650.01 in Stock

Key Points

• Insider Southpoint Capital Advisors Lp sold 20,609 shares of Fennec Pharmaceuticals at an average price of C$12.89, totaling C$265,650.01, resulting in a 0.51% decrease in their holdings.
• Fennec Pharmaceuticals' stock has declined by 6.6% recently, trading at C$12.40, below its fifty-day moving average of C$12.18.
• The company's lead product candidate, PEDMARK, aims to prevent ototoxicity in children undergoing cisplatin chemotherapy.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) insider Southpoint Capital Advisors Lp sold 20,609 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of C$12.89, for a total value of C$265,650.01. Following the completion of the transaction, the insider owned 4,010,100 shares of the company's stock, valued at approximately C$51,690,189. This trade represents a 0.51% decrease in their position.

Southpoint Capital Advisors Lp also recently made the following trade(s):

• On Tuesday, October 7th, Southpoint Capital Advisors Lp sold 26,900 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.23, for a total value of C$355,887.00.
• On Wednesday, October 8th, Southpoint Capital Advisors Lp sold 19,605 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.07, for a total value of C$256,237.35.

Fennec Pharmaceuticals Stock Down 6.6%

TSE:FRX traded down C$0.88 during mid-day trading on Friday, hitting C$12.40. 305 shares of the company's stock traded hands, compared to its average volume of 1,007. The company has a fifty day moving average of C$12.18 and a 200 day moving average of C$10.71. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$13.83. The company has a market capitalization of C$345.12 million, a P/E ratio of -27.56 and a beta of 2.48. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.